Loss of pituitary hormone function after stereotactic radiosurgery for pituitary adenomas: mechanisms and management - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Post-Stereotactic Radiosurgery Pituitary Hormone Dysfunction in Patients with Pituitary Adenomas: Understanding Mechanisms and Treatment Approaches

  • By

  • Christina Abi Faraj

  • Ian E. McCutcheon

  • June 6, 2026

Share

Clinical Scorecard: Post-Stereotactic Radiosurgery Pituitary Hormone Dysfunction in Patients with Pituitary Adenomas: Understanding Mechanisms and Treatment Approaches

At a Glance

Category

Detail

Condition

Pituitary hormone dysfunction following stereotactic radiosurgery (SRS) for pituitary adenomas.

Key Mechanisms

Hormonal dysfunction may result from damage caused by the tumor or its treatment, including SRS.

Target Population

Patients with pituitary adenomas treated with SRS, including those with functioning and nonfunctioning tumors.

Care Setting

Multidisciplinary pituitary care involving endocrinology, neurosurgery, and radiation oncology.

Key Highlights

  • SRS is used for tumor control and hormonal normalization in PAs - needs source.

Guideline-Based Recommendations

Diagnosis

  • Assess pituitary function before SRS, including evaluation for hormone hypersecretion and deficiencies.

  • After treatment, evaluate for new or worsening pituitary hormone deficiencies and distinguish these from pre-existing dysfunction.

Management

  • Surgical resection is preferred for symptomatic NFPAs and FPAs - needs source.

Monitoring & Follow-up

  • Continue long-term endocrine follow-up after SRS, as pituitary hormone deficiencies may develop after treatment.

  • Monitor pituitary hormone function periodically and assess tumor status with appropriate imaging follow-up.

  • Provide hormone replacement when deficiencies are identified, with ongoing reassessment of treatment needs.

Risks

  • New or progressive hypopituitarism is a potential late complication of SRS.

  • The risk and pattern of hormone dysfunction may vary with tumor characteristics, prior treatment, and radiation exposure to the normal pituitary gland and surrounding structures.

Patient & Prescribing Data

Patients should be informed that pituitary hormone dysfunction can occur or progress after SRS and may require long-term monitoring and hormone replacement.

Clinical Best Practices

  • Document baseline pituitary hormone function before SRS and use it to guide post-treatment assessment.

  • Coordinate follow-up among endocrinology, neurosurgery, and radiation oncology.

  • Consider surgical debulking prior to SRS for better outcomes - needs source.

Related Resources & Content

  • European Society of Endocrinology Guidelines

Original Source(s)

Related Content